Common Equity: The sum of all common equity items.
Apimeds Pharmaceuticals US, Inc. (APUS) had Common Equity of $8.16M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-1.78M |
|
-- |
|
-- |
|
$1.84M |
|
$-1.84M |
|
$0.06M |
|
$-1.78M |
|
$-1.78M |
|
$-1.78M |
|
$-1.78M |
|
$-1.78M |
|
$-1.78M |
|
$-1.84M |
|
$-1.83M |
|
12.58M |
|
12.58M |
|
$-0.14 |
|
$-0.14 |
|
| Balance Sheet Financials | |
$9.09M |
|
$0.03M |
|
$0.16M |
|
$9.25M |
|
$1.09M |
|
-- |
|
-- |
|
$1.09M |
|
|
Common Equity |
$8.16M |
$8.16M |
|
$8.16M |
|
12.58M |
|
| Cash Flow Statement Financials | |
$-5.11M |
|
$-0.04M |
|
$12.13M |
|
$0.00M |
|
$6.99M |
|
$6.98M |
|
$1.93M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.34 |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-5.14M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-21.83% |
|
-21.83% |
|
-19.26% |
|
-21.83% |
|
$0.65 |
|
$-0.41 |
|
$-0.41 |
|